Mendeley Supplemental Figure 1

Published: 30 October 2023| Version 1 | DOI: 10.17632/kfzyfrfc7m.1
Contributor:
Xing-yu Yang

Description

Supplemental material for reviewers only. Comparison of reduced Psoriasis Area Severity Index (PASI) scores with ixekizumab monoclonal antibody monotherapy, secukinumab monoclonal antibody monotherapy, and tofacitinib combination therapy at various time points.

Files

Categories

Psoriasis

Licence